LINEAGE CELL THERAPEUTICS IN (LCTX) Forecast, Price Target & Analyst Ratings

NYSEARCA:LCTX • US53566P1093

Current stock price

1.55 USD
+0.05 (+3.33%)
At close:
1.55 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for LINEAGE CELL THERAPEUTICS IN (LCTX).

Forecast Snapshot

Consensus Price Target

Price Target
$4.25
+ 174.20% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.01
Revenue Estimate
4.813M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
81.54%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$4.25
Upside
+ 174.20%
From current price of $1.55 to mean target of $4.25, Based on 13 analyst forecasts
Low
$2.02
Median
$3.06
High
$9.45

Price Target Revisions

1 Month
0.00%
3 Months
0.00%

Price Target Summary

13 Wall Street analysts provided a forecast for the next 12 months for LCTX. The average price target is 4.25 USD. This implies a price increase of 174.2% is expected in the next year compared to the current price of 1.55.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

LCTX Current Analyst RatingLCTX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6

Analyst Ratings History

LCTX Historical Analyst RatingsLCTX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
81.54%
LCTX was analyzed by 13 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about LCTX.
In the previous month the buy percentage consensus was at a similar level.
LCTX was analyzed by 13 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-06D. Boral CapitalMaintains Buy -> Buy
2026-02-09D. Boral CapitalMaintains Buy -> Buy
2025-11-25D. Boral CapitalMaintains Buy -> Buy
2025-11-24HC Wainwright & Co.Maintains Buy -> Buy
2025-08-27D. Boral CapitalMaintains Buy -> Buy
2025-08-14D. Boral CapitalMaintains Buy -> Buy
2025-08-05D. Boral CapitalMaintains Buy -> Buy
2025-06-23D. Boral CapitalMaintains Buy -> Buy
2025-06-23HC Wainwright & Co.Reiterate Buy -> Buy
2025-03-14B. Riley SecuritiesMaintains Buy -> Buy
2025-03-11D. Boral CapitalMaintains Buy -> Buy
2025-03-11HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-11D. Boral CapitalMaintains Buy -> Buy
2025-02-11HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-31HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-10Maxim GroupMaintains Buy -> Buy
2025-01-03D. Boral CapitalMaintains Buy -> Buy
2024-12-04HC Wainwright & Co.Maintains Buy -> Buy
2024-11-20D. Boral CapitalMaintains Buy -> Buy
2024-11-18D. Boral CapitalInitiate Buy
2024-08-20Craig-HallumInitiate Buy
2024-05-06HC Wainwright & Co.Reiterate Buy -> Buy
2024-03-08HC Wainwright & Co.Reiterate Buy -> Buy
2024-02-13HC Wainwright & Co.Reiterate Buy -> Buy
2024-02-05Cantor FitzgeraldReiterate Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 11, 2026
Period
Q1 / 2026
EPS Estimate
-$0.01
Revenue Estimate
4.813M
Revenue Q2Q
220.44%
EPS Q2Q
28.60%
Number of Analysts
8

Next Earnings Revisions

Revenue (1 Month)
112.78%
Revenue (3 Months)
172.69%
EPS (1 Month)
30.00%
EPS (3 Months)
30.00%

Next Earnings Summary

LCTX is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -0.01 USD and the consensus revenue estimate is 4.81M USD.
The next earnings revenue estimate has been revised upward by 172.69% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
LCTX revenue by date.LCTX revenue by date.
8.945M
-39.15%		9.499M
6.19%		14.556M
53.24%		22.671M
55.75%		23.342M
2.96%		59.212M
153.67%		90.845M
53.42%		161.47M
77.74%		281.6M
74.40%		407.68M
44.77%		569.36M
39.66%
EBITDA
YoY % growth
LCTX ebitda by date.LCTX ebitda by date.
-24.041M
-10.33%		-20.869M
13.19%		-21.08M
-1.01%		-20.094M
4.68%		-21.599M
-7.49%		-23.741M
-9.92%		-20.094M
15.36%		-15.422M
23.25%		-16.728M
-8.47%		-18.187M
-8.72%		-19.727M
-8.47%
EBIT
YoY % growth
LCTX ebit by date.LCTX ebit by date.
-24.733M
-9.83%		-21.478M
13.16%		-21.779M
-1.40%		-18.829M
13.54%		-24.26M
-28.84%		9.335M
138.48%		35.553M
280.86%		124.79M
251.00%		242.86M
94.61%		398.66M
64.15%		554.18M
39.01%
Operating Margin
LCTX operating margin by date.LCTX operating margin by date.
-276.50%-226.11%-149.62%-83.05%-103.93%15.77%39.14%77.28%86.24%97.79%97.33%
EPS
YoY % growth
LCTX eps by date.LCTX eps by date.
-0.13
13.33%		-0.10
23.08%		-0.22
-120.00%		-0.07
70.33%		-0.08
-21.88%		0.04
148.72%		0.11
189.47%		0.38
240.91%		0.67
76.00%		1.06
57.08%		1.37
29.90%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		-0.01
28.60%		-0.01
92.71%		-0.02
84.31%		-0.02-0.03
-114.29%		-0.03
-500.00%		-0.03
-25.00%		-0.03
-25.00%
Revenue
Q2Q % growth		4.813M
220.44%		9.925M
258.95%		3.295M
-10.49%		3.295M
-50.14%		1.117M
-76.79%		1.117M
-88.75%		1.117M
-66.10%		1.117M
-66.10%
EBITDA
Q2Q % growth		-5.936M
6.38%		-6.814M
-47.96%		-6.885M
-110.36%		-6.997M
-19.63%		-7.058M
-18.90%		-7.13M
-4.64%		-7.211M
-4.74%		-7.313M
-4.52%
EBIT
Q2Q % growth		-4.657M
28.41%		-3.63M
26.51%		-8.132M
-114.79%		-8.887M
-35.72%		-8.184M
-75.76%		-8.353M
-130.09%		-8.521M
-4.78%		-8.689M
2.22%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

LCTX Yearly Revenue VS EstimatesLCTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M 400M 500M
LCTX Yearly EPS VS EstimatesLCTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 0.5 -0.5 1

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
29.59%
EPS Next 5 Year
30.18%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
80.32%
Revenue Next 5 Year
74.09%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
10.59%
EBIT Next 5 Year
9.57%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

LINEAGE CELL THERAPEUTICS IN / LCTX Forecast FAQ

Can you provide the average price target for LINEAGE CELL THERAPEUTICS IN stock?

13 analysts have analysed LCTX and the average price target is 4.25 USD. This implies a price increase of 174.2% is expected in the next year compared to the current price of 1.55.

What is the next earnings date for LCTX stock?

LINEAGE CELL THERAPEUTICS IN (LCTX) will report earnings on 2026-05-11.

What are the consensus estimates for LCTX stock next earnings?

The consensus EPS estimate for the next earnings of LINEAGE CELL THERAPEUTICS IN (LCTX) is -0.01 USD and the consensus revenue estimate is 4.81M USD.

How many analysts cover LINEAGE CELL THERAPEUTICS IN (LCTX) stock?

The number of analysts covering LINEAGE CELL THERAPEUTICS IN (LCTX) is 13.